Metallothionein induction prevents toxic side effects of cisplatin and adriamycin used in combination.
The protective effects of metallothionein (MT) preinduction by bismuth subnitrate (BSN) against the renal toxicity of cis-diamminedichloroplatinum (cis-DDP), the cardiotoxicity of adriamycin (ADR), and the lethal and bone marrow toxicities of these drugs were observed in mice receiving cis-DDP and ADR simultaneously. Preinduction of MT biosynthesis by BSN, which is currently used as an antidiarrheal drug, did not affect the antitumor activities of the two drugs, suggesting that the beneficial effects of the preinduction of MT biosynthesis by BSN may be applicable for therapy involving cis-DDP and ADR, either alone or in combination.
Satoh
M
M
Department of Public Health, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan.
Naganuma
A
A
Imura
N
N
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001729:Bismuth / Q000008:administration & dosage*; D002286:Carcinoma, Ehrlich Tumor / Q000188:drug therapy; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects; D003110:Colonic Neoplasms / Q000188:drug therapy; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D006321:Heart / Q000187:drug effects; D007668:Kidney / Q000187:drug effects; D008297:Male; D008668:Metallothionein / Q000096:biosynthesis*; D051379:Mice; D008813:Mice, Inbred ICR
D004317:Doxorubicin; D008668:Metallothionein; C010804:bismuth subnitrate; D002945:Cisplatin; D001729:Bismuth